In other countries
The same active substances on other registers, the same brand first.
- EmgalityBrazil · Libbs Farmacêutica LtdaSame brand
- EmgalityBrazil · Eli Lilly do Brasil LtdaSame brand
- EmgalityCanada · 120 MG / ML · Solution · Eli Lilly Canada INCSame brand
- EmgalityCanada · 120 MG / ML · Solution · Eli Lilly Canada INCSame brand
- EmgalityCanada · 100 MG / ML · Solution · Eli Lilly Canada INCSame brand
- Emgality 120 MG Solucion Inyectable en Pluma PrecargadaSpain · 120 mg/ml · solución inyectable · Eli Lilly Nederland B.V.Same brand
- Emgality 120 MG Solucion Inyectable en Jeringa PrecargadaSpain · 120 mg/ml · solución inyectable · Eli Lilly Nederland B.V.Same brand
- EmgalityEuropean Union · Eli Lilly Nederland B.V.Same brand
- EmgalityCroatiaSame brand
- EmgalityItaly · Soluzione iniettabile · Eli Lilly Nederland B.V.Same brand
- Emgality 120 mg/ml, oplossing voor injectie in een voorgevulde penNetherlands · Oplossing voor injectie · Eli Lilly Nederland B.V.Same brand
- EmgalitySaudi Arabia · Eli LillySame brand
- EmgalitySaudi Arabia · Eli LillySame brand
- Emgality Solution for Injection in Pre-Filled Pen 120 MG/MLSingapore · 120 mg/ml · injection, solution · DKSH Singapore Pte. LTD.Same brand
- Emgality Solution for Injection in Pre-Filled Syringe 100 MG/MLSingapore · 100 mg/ml · injection, solution · DKSH Singapore Pte. LTD.Same brand
- EMGALITY injection 100mg/mLTaiwan · 注射液劑 · 台灣禮來股份有限公司Same brand
Documents
The official texts, at the regulator.
Sources and licences
Compiled by Prognia from the public register below; the register’s text is the official one.
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026
Report an error or request removalCorrections from the holder or the register are welcome.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Active substance
- Galcanezumab
- Strength
- 100MG/ML
- Dosage form
- Injection
- Route
- Subcutaneous
- Register
- United States (FDA)
- Status
- Marketed
- Status in the register
- Licensed / Rx
- Authorised
- 4 Jun 2019
- Registration
- BLA 761063
- Marketing authorisation holder
- Eli Lilly and Company
- Procedure
- 351(a)
- Supply
- Rx